Page last updated: 2024-11-04

pyridoxal phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyridoxal phosphate (PLP) is a coenzyme derived from vitamin B6. It plays a crucial role in over 140 enzymatic reactions, primarily involved in amino acid metabolism. PLP acts as a cofactor for various enzymes, including transaminases, decarboxylases, and racemases. It is synthesized from pyridoxine (vitamin B6) in a two-step enzymatic process. PLP is vital for various metabolic pathways, including glucose metabolism, neurotransmitter synthesis, and heme biosynthesis. The importance of PLP in cellular function makes it a subject of extensive research, with studies exploring its role in various diseases, such as neurological disorders, cardiovascular diseases, and cancer. Research on PLP focuses on its potential therapeutic applications, including treatment of neurological disorders and inflammatory conditions.'

Pyridoxal Phosphate: This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyridoxal 5'-phosphate : The monophosphate ester obtained by condensation of phosphoric acid with the primary hydroxy group of pyridoxal. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1051
CHEMBL ID82202
CHEBI ID18405
SCHEMBL ID23158
MeSH IDM0018242
PubMed CID38882
CHEMBL ID3181870
CHEBI ID192625
SCHEMBL ID827100
MeSH IDM0018242

Synonyms (214)

Synonym
einecs 200-208-3
2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate trihydrate
pyridoxal phosphate [jan]
nsc 82388
CHEMBL82202 ,
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate
CHEBI:18405 ,
3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde
pyridoxal 5'-(dihydrogen phosphate)
pyridoxal 5-monophosphoric acid ester
3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate
pyridoxal phosphate treated .beta.-lactoglobulin from bovine whey
phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin-3-ylmethyl) ester
mc-1
pyridoxal 5'-phosphate hydrate
pyridoxal 5'-phosphate monohydrate - vitamin b6
SGCUT00188
4-formyl-5-hydroxy-6-methyl-pyridin-3-yl)methoxyphosphonic acid
pyridoxal-5'-phosphate
sechvitan, vitahexin p
codecarboxylase
pal-p
pyridoxal, 5-(dihydrogenphosphate)
biosechs
apolon b6
p-5'-p
hairoxal
vitazechs
pyromijin
(4-formyl-5-hydroxy-6-methyl-3-pyridyl)methyl dihydrogen phosphate
nsc82388
hiadelon
pydoxal
pyridoxal, 5-(dihydrogen phosphate)
pyridoxal p
pidopidon
sechvitan
sri 2392
nsc-82388
pyridoxyl phosphate
hexermin-p
hi-pyridoxin
isonicotinaldehyde, 5-(dihydrogen phosphate)
piodel
phosphopyridoxal
himitan
phosphopyridoxal coenzyme
4-pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-
vitahexin-p
phosphoridoxal coenzyme
pyridoxal phosphate (6ci)
2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine-5-calcium phosphate
4-pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-
2-methyl-3-hydroxy-4-formyl-5-pyridylmethylphosphoric acid
pyridoxaldehyde phosphate
vitahexin p
coenzyme b6
3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde
pyridoxal monophosphate
hexermin p
vitamin b6 phosphate (ester)
vitamin b6 phosphate
4-pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]- (9ci)
pyridoxal, 5-(dihydrogen phosphate) (8ci)
apolon b(sub 6)
54-47-7
pyridoxal 5'-phosphate
pyridoxal 5-phosphate
PLP ,
pyridoxal-p
pyridoxal-5p
C00018
pyridoxal phosphate
p5p ,
pyridoxal 5'-phosphate hydrate, >=98%
pyridoxal 5'-phosphate monohydrate, vitamin b6
TO_000077
pyridoxal 5'-phosphate hydrate, powder, bioreagent, suitable for cell culture
pyridoxal phosphate anhydrous
DB00114
NCGC00166300-01
A26BDB6A-282A-4D13-A916-7B2B215B0FD6
pyridoxal-5-monophosphate
pyridoxal 5''-phosphate
bdbm50118216
pyridoxal 5''-(dihydrogen phosphate)
pyridoxal-5-phosphate
BMSE000111
FT-0655876
853645-22-4
(4-methanoyl-6-methyl-5-oxidanyl-pyridin-3-yl)methyl dihydrogen phosphate
(4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate
A841303
(4-formyl-5-hydroxy-6-methyl(3-pyridyl))methyl dihydrogen phosphate
3-hydroxy-2-methyl-5-([phosphonooxy]methyl)-4-pyridinecarboxaldehyde
f06sge49m6 ,
unii-f06sge49m6
FT-0631236
pyridoxal 5'-phosphate [vandf]
pyridoxal 5-phosphate [inci]
pyridoxal phosphate [who-dd]
vitamin b6 (pyridoxal 5-phosphate)
pyridoxal 5-phosphate [mi]
AKOS015891654
S5311
gtpl5249
[(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methoxy]phosphonic acid
pyridoxalphosphate
pridoxal-5-phosphate
SCHEMBL23158
DTXSID4048351
Q-201645
CS-7767
pyridoxal 5 inverted exclamation marka-phosphate hydrate
pyridoxal 5'-phosphate 5
EX-A980
sr-01000944534
SR-01000944534-1
pyridoxal-phosphate
F17391
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyldihydrogenphosphate
HY-B1744
3-hydroxy-2-methyl-5-([phosphonooxy]methyl)-4-pyridinecarbaldehyde
Q418957
pyridoxal phosphate
pyridoxal 5'-phosphate anhydrous
mfcd00006333
AS-19314
pyridoxal 5 inverted exclamation marka-phosphate
STL185213
SB18794
BCP34576
pyridoxal 5'-phosphate;codecarboxylase
CCG-266929
pyridoxal 5'-phosphate;pyridoxyl phosphate
4-pyridinecarboxaldehyde,3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-
pyridoxal 5-phosphate;pyridoxyl phosphate
pyridoxal 5/'-phosphate (hydrate)
EN300-6474442
Z1741970251
SY065874
pyridoxal, 5-(dihydrogen phosphate), monohydrate
pyridoxal-5-phosphate, monohydrate
pyridoxal-5-monophosphoric acid ester monohydrate
3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde monohydrate
pyridoxyl phosphate monohydrate
4-pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-, monohydrate
phosphopyridoxal monohydrate
3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate monohydrate
cardoxal
tardoxal
avastrem
pyridoxal phosphate monohydrate
hipyridoxin (tn)
pyridoxal phosphate hydrate (jp17)
D00006
41468-25-1
pyridoxal 5'-phosphate monohydrate, >=97.0% (nt)
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate hydrate
FT-0639717
CHEBI:192625
pyridoxal 5-phosphate monohydrate
(4-ormyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate;hydrate
tox21_112399
cas-41468-25-1
dtxcid5026594
pyridoxal 5'-phosphate monohydrate
dtxsid7046594 ,
5v5ioj8338 ,
unii-5v5ioj8338
pyridoxal-5-phosphate monohydrate
S4871
3-hydroxy-2-methyl-5-((phosphonoxy)methyl)-4-pyridinecarboxaldehyde hydrate
pyridoxal phosphate hydrate
pyridoxal phosphate [mart.]
pyridoxal 5-phosphate monohydrate [who-dd]
pyridoxal phosphate hydrate [jan]
4-pyridinecarboxaldehyde, 3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-, hydrate (1:1)
SCHEMBL827100
NCGC00166300-02
tox21_112399_1
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate hydrate(1:x)
AKOS024370824
AC-30878
CHEMBL3181870
mfcd00149414
pyridoxal-5'-phosphate monohydrate
J-524134
phosphoric acid mono-(4-formyl-5-hydroxy-6-methyl-pyridin--ylmethyl) ester; compound with genericinorganic neutral component
BCP20447
pyridoxal-5'
pyridoxal 5'-phosphate (hydrate)
Q27888204
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate xhydrate(1:x)
(4-formyl-5-hydroxy-6-methyl-3-pyridyl)methyl dihydrogen phosphate monohydrate
CEEQUQSGVRRXQI-UHFFFAOYSA-N
BCP14972
3-hydroxy-2-methyl-5-([phosphonooxy]methyl)-4-pyridinecarboxaldehyde monohydrate
pyridoxal phosphate (hydrate)
AMY22229
CCG-267094
pyridoxal phosphate (monohydrate)
pyridoxal 5'-phosphate (monohydrate)
pyridoxal 5'-?phosphate (monohydrate)
HY-W011727A
CS-0099254
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate;hydrate
D87584
SY061598
pyridoxal 5 inverted exclamation mark -phosphate monohydrate
3-hydroxy-2-methyl-5-[(phosphonooxy)-methyl]-4-pyridinecarboxaldehyde,monohydrate
pyridoxal 5'-hosphate (monohydrate)
(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyldihydrogenphosphatehydrate
c8h12no7p

Research Excerpts

Overview

Pyridoxal phosphate (PLP) is a covalently bound cofactor of glycogen phosphorylase. It is a potent probe for exploring the "sidedness" of proteins in the membrane of the intact red blood cell.

ExcerptReferenceRelevance
"Pyridoxal phosphate (PLP) is an enzyme cofactor required for the chemical transformation of biological amines in many central cellular processes. "( Mining the cellular inventory of pyridoxal phosphate-dependent enzymes with functionalized cofactor mimics.
Bach, NC; Hoegl, A; Kirsch, VC; Nodwell, MB; Pfanzelt, M; Schneider, S; Sieber, SA; Stahl, M, 2018
)
2.2
"Pyridoxal phosphate is a covalently bound cofactor of glycogen phosphorylase. "( Low muscle levels of pyridoxine in McArdle's syndrome.
Cook, JD; Dempsey, WB; Feit, H; Haller, RG; Knochel, JP, 1983
)
1.71
"Pyridoxal phosphate is a potent probe for exploring the "sidedness" of proteins in the membrane of the intact red blood cell. "( Pyridoxal phosphate. An anionic probe for protein amino groups exposed on the outer and inner surfaces of intact human red blood cells.
Balshin, M; Breuer, W; Cabantchik, IZ; Rothstein, A, 1975
)
3.14

Effects

Pyridoxal phosphate has a role in regulating cellular calcium transport through both the voltage-mediated and ATP-mediated purinergic mechanisms of cellular calcium influx. It has a similar effect in the intracellular millieu and thus, 3.

Pyridoxal phosphate has all the features of suppressing such risk factors for stone formation in patients with idiopathic hypercalciuria. It has a role in regulating cellular calcium transport through both the voltage-mediated and ATP-mediated purinergic mechanisms of cellular calcium influx.

ExcerptReferenceRelevance
"Pyridoxal phosphate has a role in regulating cellular calcium transport through both the voltage-mediated and ATP-mediated purinergic mechanisms of cellular calcium influx and, hence, has a role in the control of hypertension."( Antihypertensive and neuroprotective actions of pyridoxine and its derivatives.
Dakshinamurti, K; Dakshinamurti, S, 2015
)
1.14
"pyridoxal phosphate has a similar effect in the intracellular millieu and thus, 3."( Pyridoxal-5-phosphate affects glucocorticoid receptors in intact lymphocytes similarly as in cell-free systems.
Báthori, G; Náray, A, 1982
)
0.99
"Pyridoxal phosphate has a role in regulating cellular calcium transport through both the voltage-mediated and ATP-mediated purinergic mechanisms of cellular calcium influx and, hence, has a role in the control of hypertension."( Antihypertensive and neuroprotective actions of pyridoxine and its derivatives.
Dakshinamurti, K; Dakshinamurti, S, 2015
)
1.14
"pyridoxal phosphate has a similar effect in the intracellular millieu and thus, 3."( Pyridoxal-5-phosphate affects glucocorticoid receptors in intact lymphocytes similarly as in cell-free systems.
Báthori, G; Náray, A, 1982
)
0.99
"Pyridoxal phosphate, which has served as an affinity label for nucleotide binding sites on other enzymes, demonstrated a major site of substitution at the center of the protein's DNA binding cleft adjacent to lysine 46 as well as two other reaction sites near residues implicated in DNA binding."( X-ray studies of nucleotide binding and pyridoxal phosphate labeling of the gene 5 DNA unwinding protein.
Axelrod, H; Greene, SM; McPherson, A, 1986
)
1.26
"Pyridoxal phosphate has all the features of suppressing such risk factors for stone formation in patients with idiopathic hypercalciuria."( Effect of high-calcium diet on urinary oxalate excretion in urinary stone formers.
Furuta, H; Katayama, T; Nakada, T; Sasagawa, I; Shimazaki, J, 1988
)
1

Actions

ExcerptReferenceRelevance
"Pyridoxal phosphate enzymes catalyze a wide variety of reaction types on amines and amino acids, generally by stabilizing carbanionic intermediates. "( Reaction specificity in pyridoxal phosphate enzymes.
Toney, MD, 2005
)
2.08

Treatment

Pyridoxal phosphate (PAL-P) treatment was effective in 9 of 70 (12.9%) prenatal cases and 5 of 18 (27.8%) idiopathic cases.

ExcerptReferenceRelevance
"Pyridoxal phosphate-treated receptors had little affinity for hydroxylapatite, phosphocellulose, and DNA-cellulose."( Comparison of pyridoxal phosphate and 0.4 M KCl-extracted nuclear glucocorticoid receptors in HeLa S3 cells.
Budziak, TE; Cidlowski, JA; Currie, RA, 1983
)
1.35
"Pyridoxal phosphate and NaBH4 treated receptors prepared in buffer B sediment as disperse 3-6S species when analyzed in buffer A gradients."( Pyridoxal phosphate blocks aggregation of molybdate treated glucocorticoid receptors in HeLa S3 cells.
Cidlowski, JA; Currie, RA, 1982
)
2.43
"Pyridoxal phosphate (PAL-P) treatment was effective in 9 of 70 (12.9%) prenatal cases and 5 of 18 (27.8%) idiopathic cases.(ABSTRACT TRUNCATED AT 250 WORDS)"( Prenatal etiologies of West syndrome.
Ohtahara, S; Ohtsuka, Y; Oka, E; Sato, M; Yamatogi, Y; Yoshinaga, H,
)
0.85
"Treatment with pyridoxal phosphate also decreased DNA-binding of the complex, being present either before or after heat- and salt-activation."( Pyridoxal-5-phosphate affects glucocorticoid receptors in intact lymphocytes similarly as in cell-free systems.
Báthori, G; Náray, A, 1982
)
0.6

Toxicity

ExcerptReferenceRelevance
"Pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, readily forms complexes with a wide variety of potentially toxic substances, including cyanide (KCN), spermine (SPM), gentamicin (GM), and dopamine (DOP)."( Pyridoxal 5'-phosphate as an antidote for cyanide, spermine, gentamicin, and dopamine toxicity: an in vivo rat study.
Cabellon, S; Keniston, RC; Yarbrough, KS, 1987
)
0.27
" The authors conclude that slow administration of 5 mumol/kg Mn-DPDP at a concentration of 10 mumol/mL is safe and efficient enough to proceed to further clinical trials."( Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients.
Aicher, KP; Claussen, CD; Duda, SH; Grönewäller, E; Kopp, AF; Laniado, M,
)
0.13
" Adverse events were reported for 23% of the patients; most were mild to moderate in intensity, did not require treatment, and were not drug related."( Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety).
Anderson, MW; Borello, JA; Bova, JG; Brown, JJ; Chezmar, JL; Dachman, AH; Federle, MP; Fenstermacher, M; Foster, GS; Francis, IR; Freeny, PC; Halford, HH; Harmon, B; Harms, SE; Johnson, CD; Kenney, PJ; Klippenstein, DL; Lee, JK; Mattrey, R; Mitchell, DG; Pelsang, RE; Rubin, DL; Saini, S; Semelka, RC; Turner, DA; Weinreb, JC, 2000
)
0.31
" Minor adverse reactions, including nausea (1%-2% for all agents) and hives (<1% for all agents), occur in a very low percent of cases."( Safety of approved MR contrast media for intravenous injection.
Runge, VM, 2000
)
0.31
" These findings suggest that UVA-induced vitamin B6 cytotoxicity is caused by toxic photoproducts resulting from irradiated vitamin B6."( Vitamin B6 phototoxicity induced by UVA radiation.
Kosaka, H; Maeda, T; Minami, H; Sato, K; Shiga, T; Taguchi, H; Yoshikawa, K, 2000
)
0.31
" Adverse events and discomfort were recorded and graded in all patients."( Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis.
de Beeck, BO; Fagertun, H; Fog, AF; Kane, P; Martí-Bonmatí, L, 2003
)
0.32
" This regimen was introduced in the 1970s and has remained largely unchanged even though the initial NAC infusion is frequently associated with adverse reactions, in particular nausea, vomiting, and anaphylactoid reactions."( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi
Dear, J, 2019
)
0.51
" This study will provide valuable data regarding the incidence of adverse events caused by the 12-h NAC plus PP100-01 regimen and may provide evidence of PP100-01 efficacy in the treatment of paracetamol-induced liver injury."( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi
Dear, J, 2019
)
0.51
" Primary endpoints: all participants experienced ≥1 adverse event (AE), most commonly gastrointestinal."( Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial).
Black, P; Dear, JW; Gallagher, B; Grahamslaw, J; Henriksen, D; Lee, RJ; Morrison, EE; O'Brien, R; Oatey, K; Oosthuyzen, W; Weir, CJ, 2019
)
0.51
"Fomepizole (4-methylpyrazole) is safe and has shown efficacy in preclinical models, human hepatocytes and in volunteers against APAP overdose."( Novel strategies for the treatment of acetaminophen hepatotoxicity.
Akakpo, JY; Jaeschke, H; Ramachandran, A, 2020
)
0.56
"It is challenging for physicians to prescribe a safe dose of B6 supplements because of the narrow therapeutic index."( Preventing Vitamin B6-Related Neurotoxicity.
Reddy, P,
)
0.13
" Although several studies have reported serious adverse events following PLP treatment, no study has investigated the risk factors for such occurrences."( Identifying risk factors for adverse events of pyridoxal phosphate in infantile epileptic spasms syndrome.
Arai, Y; Kanai, S; Maegaki, Y; Noma, H; Ohta, K; Okanishi, T; Sunada, H, 2023
)
1.17
"To investigate adverse events associated with PLP therapy for the treatment of IESS and to identify the associated risk factors."( Identifying risk factors for adverse events of pyridoxal phosphate in infantile epileptic spasms syndrome.
Arai, Y; Kanai, S; Maegaki, Y; Noma, H; Ohta, K; Okanishi, T; Sunada, H, 2023
)
1.17
"We retrospectively evaluated adverse events in 59 patients with IESS at Tottori University Hospital between January 1995 and September 2022."( Identifying risk factors for adverse events of pyridoxal phosphate in infantile epileptic spasms syndrome.
Arai, Y; Kanai, S; Maegaki, Y; Noma, H; Ohta, K; Okanishi, T; Sunada, H, 2023
)
1.17
"9%) participants experienced adverse events, including vomiting in 16 participants (59."( Identifying risk factors for adverse events of pyridoxal phosphate in infantile epileptic spasms syndrome.
Arai, Y; Kanai, S; Maegaki, Y; Noma, H; Ohta, K; Okanishi, T; Sunada, H, 2023
)
1.17

Pharmacokinetics

ExcerptReferenceRelevance
" Furthermore, the clearance of large polymers appeared to be highly dose-dependent: after 20% and 70% exchange transfusions, we observed for large polymers a plasma half-life of 12 and 26 hours, respectively, whereas the half-life for 64 kD monomers was 4 hours in both cases."( Effect of polymerization on clearance and degradation of free hemoglobin.
Agterberg, J; Bakker, JC; Berbers, GA; Bleeker, WK; den Boer, PJ; Rigter, G, 1992
)
0.28
" Plasma clearance and volume of distribution of PLP decreased significantly after supplementation, but half-life t 1/2 did not change."( Relationship between body store of vitamin B6 and plasma pyridoxal-P clearance: metabolic balance studies in humans.
Aronoff, GR; Li, TK; Lui, A; Lumeng, L, 1985
)
0.27
" When planning a pharmacokinetic investigation of an endogenous substance exogenously administered, it is imperative to carefully ascertain the above mechanisms as well as the baseline value and their possible variations associated with daily rhythm, food, age, sex, menstrual cycle."( Some pharmacokinetic considerations about homeostatic equilibrium of endogenous substances.
Arrigoni Martelli, E; Marzo, A; Rescigno, A,
)
0.13
"The manganese (Mn) moiety is rapidly removed from plasma with an elimination half-life of less than 25 min in both species, reflecting a rapid distribution to the tissues and an early excretion."( Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration.
Grant, D; Hustvedt, SO; Southon, TE; Zech, K, 1997
)
0.3
"To determine the pharmacokinetic (PK) profile of manganese (Mn) after a 2-hour intravenous infusion of mangafodipir at 5 micromol/kg body weight and to correlate Mn concentrations with oxidative stress, early decrease in serum total bilirubin concentration, and prothrombin time (PT) in chronic alcoholic patients with acute alcoholic hepatitis."( Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.
Batteux, F; Debray, M; Hirt, D; Laurent, A; Pavlovic, S; Poupon, J; Richardet, JP; Sogni, P; Treluyer, JM; Urien, S; Weill, B, 2009
)
0.35
"The pharmacokinetic profile of Diclectin well explains its documented delayed efficacy."( Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
Koren, G; Nulman, I, 2009
)
0.35
" For the purpose of this study, pharmacokinetic values for DOX and PLP were adjusted for body weight."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.37
" The estimated elimination half-life (t(1/2)) was 92."( A randomized, double-blind, crossover study on the pharmacokinetics of a novel formulation of CoQ₁₀ with pyridoxal 5'-phosphate and phosphatidyl choline.
Evans, M; Guthrie, N; Sharma, P, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aim of the study was to investigate the influence of PP alone and in combination with various doses of vigabatrin (VGB) on brain GABA levels."( Influence of pyridoxal 5'-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy.
Boesiger, P; Mueller, SG; Weber, OM; Wieser, HG, 2001
)
0.31
" In the present project, the authors have studied whether MC-1, an analog of PLP, alone or in combination with the thrombolytic agent tissue plasminogen activator (tPA), can protect the brains of rats injured by ischemia."( Role of MC-1 alone and in combination with tissue plasminogen activator in focal ischemic brain injury in rats.
Noor, R; Shuaib, A; Wang, CX; Yang, T, 2005
)
0.33
" HPP patients exhibit various presentations depending on their age at onset, such as infantile HPP combined with vitamin B6-responsive seizures."( Infantile hypophosphatasia combined with vitamin B6-responsive seizures and reticular formation lesions on magnetic resonance imaging: A case report.
Baba, H; Doi, T; Fukazawa, M; Masumoto, N; Mihara, F; Mizuno, Y; Nakayama, H; Sasazuki, M; Tezuka, J; Tsutsumi, Y, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" The gastric emptying rates of dosage forms were extremely prolonged in beagle dogs after drug administration postprandially, and this restricted the use of beagle dogs as an animal model in bioavailability tests."( Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates.
Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1988
)
0.27
"Research was conducted to evaluate the merits of rat bioassays in studies concerning the bioavailability of vitamin B-6."( Efficacy of the rat bioassay for the determination of biologically available vitamin B-6.
Gregory, JF; Litherland, SA, 1986
)
0.27
"The effects of cellulose, pectin and bran on the bioavailability of pyridoxine (PN) were examined using rat and chick bioassay methods."( Effects of selected polysaccharides on the bioavailability of pyridoxine in rats and chicks.
Damron, BL; Gregory, JF; Nguyen, LB, 1981
)
0.26
"The effect of cooked wheat bran on the bioavailability of vitamin B-6 (B-6) was determined in 10 men, aged 20 to 35 years."( The effect of wheat bran on the bioavailability of vitamin B-6 in young men.
Leklem, JE; Lindberg, AS; Miller, LT, 1983
)
0.27
"Relative bioavailability of vitamin B-6 from tuna, whole wheat bread and peanut butter was investigated in eight men."( Comparative vitamin B-6 bioavailability from tuna, whole wheat bread and peanut butter in humans.
Kabir, H; Leklem, JE; Miller, LT, 1983
)
0.27
"The effects of food composition and thermal processing on the relative bioavailability of vitamin B-6 in beef, spinach, potato, and cornmeal were assessed by a series of rat bioassays."( Effects of food composition on the bioavailability of vitamin B-6 in the rat.
Gregory, JF; Nguyen, LB, 1983
)
0.27
" The effect of food on the gastric emptying rate of a solution appears to be almost uniform, whereas that for a tablet is so unpredictable that a reliable absorption rate for an enteric-coated tablet cannot be expected, particularly under pre- and post-meal conditions."( Variability in absorption lag time of pyridoxal phosphate under fasting and pre- and post-meal conditions.
Nagai, N; Ogata, H; Shimamura, H; Sugito, K; Takahashi, H, 1994
)
0.56
" For direct assessment of how the bioavailability of vitamin B-6 is affected by aging, [2H]pyridoxine was orally administered to healthy men, aged 20-30 and 60-70 y, who were fed a controlled diet."( Bioavailability of vitamin B-6 in young and older men.
Ferroli, CE; Trumbo, PR, 1994
)
0.29
"An HPLC method for determining total pyridoxal from plasma was developed for a relative bioavailability comparison of two oral vitamin B6 (pyridoxine HCl) preparations."( Determination of total pyridoxal in human plasma following oral administration of vitamin B6 by high-performance liquid chromatography with post-column derivatization.
Mascher, H, 1993
)
0.29
"Previous research has shown that the pyridoxine glucoside (PNG) form of vitamin B-6 has a reduced bioavailability compared with pyridoxine, but its effect on vitamin B-6 status has not been assessed."( Vitamin B-6 status indicators decrease in women consuming a diet high in pyridoxine glucoside.
Hansen, CM; Leklem, JE; Miller, LT, 1996
)
0.29
" On the contrary, PN-beta-Glc poorly served as vitamin B6 source, because average bioavailability was only about 22% in comparison to that of PN (100%)."( Feeding experiments of pyridoxine derivatives as vitamin B6.
Hayakawa, T; Maeno, M; Morimoto, Y; Suzuki, Y; Tsuge, H, 1997
)
0.3
" This report using fluorescein isothiocyanate dextran 4000 (FD-4) as the model compound is the first to investigate the effects of purine nucleotides on absorption of poorly absorbed drugs from intestine."( Activation of P2Y receptor enhances high-molecular compound absorption from rat ileum.
Kinoshita, N; Mizuno, N; Shinozuka, K; Tada, S; Takahashi, K; Takahashi, T, 2006
)
0.33
" Pyridoxal-phosphate-6-azophenyl-2', 4'-disulfonate (PPADS) is a highly bioavailable purinoceptor inhibitor."( Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS).
Abreu-Lanfranco, O; Arora, G; Aurora, G; Dranoff, JA; Jain, D; Kruglov, EA; Nguyen, T,
)
0.13
"Diclectin exhibited similar oral bioavailability to those of the oral solutions."( Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
Koren, G; Nulman, I, 2009
)
0.35
"To determine the pharmacokinetics of DOX and pyridoxine after oral administration of two tablets of this drug combination in the form of Diclectin and to calculate their respective relative bioavailability by comparison with intravenous administration in another population."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.37
" Based on literature values of the PLP-AUC0→∞ after intravenous administration and data from the current study, the relative bioavailability of pyridoxine in Diclectin was calculated at 100%."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.37
" Using literature values and data from the current study, we estimated the oral bioavailability of pyridoxine to be 100%."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.37
" P6C forms a complex with pyridoxal phosphate (PLP), a key vitamer of pyridoxine, thereby reducing PLP bioavailability and subsequently causing epilepsy."( Inherited Disorders of Lysine Metabolism: A Review.
Bouchereau, J; Schiff, M, 2020
)
0.86
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The pharmacokinetics of a sustained release (SR) formulation of pyridoxal phosphate of buflomedil (Pirxane retard) has been studied. The gastric emptying rates of oral dosage forms were studied in humans and beagle dogs.

ExcerptRelevanceReference
"The pharmacokinetics of a sustained release (SR) formulation of pyridoxal phosphate of buflomedil (Pirxane retard) has been studied after oral administration to healthy volunteers using among else a gaschromatographic dosage method."( Pharmacokinetics of a sustained release formulation of pyridoxal phosphate of buflomedil after single or repeated oral doses in healthy volunteers.
Borgonovo, E; Covini, D; de Bernardi di Valserra, M; Feletti, F; Germogli, R, 1992
)
0.77
" If these data apply to humans, B6 deficiency may contribute to chronic theophylline toxicity; however, pyridoxine administration in the dosage used may not prevent toxicity."( Depression of vitamin B6 levels due to theophylline.
Enriquez, JI; Keniston, RC; McNamee, GA; Weir, MR, 1990
)
0.28
"The gastric emptying rates of oral dosage forms of different sizes were studied in humans and beagle dogs measuring of marker drugs such as acetaminophen, aspirin and pyridoxal phosphate in plasma or urine."( Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates.
Aoyagi, N; Ejima, A; Kaniwa, N; Ogata, H, 1988
)
0.47
" Analysis of dose-response curves (dietary vitamin B-6 vs."( Efficacy of the rat bioassay for the determination of biologically available vitamin B-6.
Gregory, JF; Litherland, SA, 1986
)
0.27
" Dose-response curves for growth, feed consumption, feed efficiency and either lever pyridoxal 5'-phosphate (PLP) or erythrocyte aspartate aminotransferase (Asp-AT) activity and PLP stimulation in vitro were compared among animals fed experimental diets varying in dietary fiber source and suboptimal levels."( Effects of selected polysaccharides on the bioavailability of pyridoxine in rats and chicks.
Damron, BL; Gregory, JF; Nguyen, LB, 1981
)
0.26
" Within each protein subgroup, graded levels of pyridoxine (PN) were added to basal diets to obtain standard PN dose-response curves."( Effects of food composition on the bioavailability of vitamin B-6 in the rat.
Gregory, JF; Nguyen, LB, 1983
)
0.27
" As the dosage was increased the percentage of 3H in the muscle, present as PN increased and that in PNP decreased."( Transport and metabolism of pyridoxine in the perfused small intestine and the hind limb of the rat.
Buss, DD; Hamm, MW; Henderson, LM; Mehansho, H, 1980
)
0.26
" There was no correlation of pyridoxal phosphate level with phenelzine daily dosage over the range of 30 mg to 90 mg."( Phenelzine reduces plasma vitamin B6.
Bowen, RC; Hawkes, J; Hussein, M; Malcolm, DE; O'Donovan, C; Yu, PH, 1994
)
0.58
" In view of the evidence for the role of excitatory amino acids in destruction of CNS nerve cells, the optimal treatment must counteract the raised levels of CSF glutamate and the dosage of vitamin B6 must be adjusted accordingly."( Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine.
Baumeister, FA; Egger, J; Gsell, W; Shin, YS, 1994
)
0.29
" Skeletal malformations, identical to those seen in the previous study, were increased in a dose-dependent manner with the highest incidence occurring in fetuses from females dosed from days 15-17 of gestation."( Developmental toxicity of mangafodipir trisodium and manganese chloride in Sprague-Dawley rats.
Blazak, WF; Gray, TJ; Treinen, KA, 1995
)
0.29
" PPADS (3-100 microM) attenuated vasodilator responses to the P2Y-selective agonists 2MeSATP and ADP, shifting the dose-response curves to the right."( Discrimination by PPADS between endothelial P2Y- and P2U-purinoceptors in the rat isolated mesenteric arterial bed.
Burnstock, G; Ralevic, V, 1996
)
0.29
" No sex differences in metabolic pattern were observed in any of the three dosage groups."( Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs.
Friisk, GA; Grant, D; Hustvedt, SO; Skotland, T; Toft, KG,
)
0.13
"In rat liver and pig organs both compounds produced a positive dose-response in R1 and tissue Mn concentration, and only small or no response in R2."( NMR relaxation studies with MnDPDP.
Bjørnerud, A; Grant, D; Martinsen, I; Moen, OM; Refsum, H; Southon, TE; Spilling, B, 1997
)
0.3
" The good response to a small dosage of ACTH might be due to some responsiveness of the high-dose pyridoxal phosphate and the underlying cause of tuberous sclerosis with normal development before onset."( A case of West syndrome well controlled by very short and low-dose ACTH therapy.
Kimura, M; Miyamoto, S; Sejima, H; Yamaguchi, S, 1999
)
0.52
" Our study established the dose-response relationship for convulsions due to isoniazid and theophylline in mice and determined if pyridoxine antagonized such seizures."( Seizures induced by theophylline and isoniazid in mice.
Bonner, AB; Peterson, SL; Weir, MR, 1999
)
0.3
" Dose-response relationships for evodiamine, rutaecarpine and capsaicin were obtained."( The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors.
Hoshikuma, K; Kamiya, T; Kobayashi, Y; Nakano, Y; Yokoo, Y, 2001
)
0.31
" The combination PP and low-medium dosed VGB (1000-2000 mg/d) did not increase the GABA+/Cr signals."( Influence of pyridoxal 5'-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy.
Boesiger, P; Mueller, SG; Weber, OM; Wieser, HG, 2001
)
0.31
" Increasing the external Ca(2+) concentration to 10 mM shifted the dose-response relationship to the right."( Excitatory effect of ATP on acutely dissociated ventromedial hypothalamic neurons of the rat.
Akaike, N; Ishibashi, H; Moritoyo, T; Sorimachi, M, 2001
)
0.31
" The inhibitory effect of the maximum bladder contraction pressure by the pyridoxalphosphate-6-azophenyl-2', 4'-disulphonate (PPADS) dosage after the atropine dosage was not recognized it in the control group, but the effect was recognized powerfully in the obstructed group."( [Acceleration of ATP-induced contraction in the obstructed bladder of the rat].
Kato, T; Otomo, R; Sato, K; Sato, S; Shimoda, N; Wada, H, 2003
)
0.32
" Dose-response curves were fit with nonlinear regression analysis to calculate the EC(50) and slope."( Acidosis attenuates P2X purinergic vasoconstriction in skeletal muscle arteries.
Buckwalter, JB; Clifford, PS; Hamann, JJ; Kluess, HA, 2005
)
0.33
" There were only small differences in myocardial R1 responses between the three doses investigated, which was contrasted by a marked dose-response in liver tissue."( Relaxation enhancing properties of MnDPDP in human myocardium.
Haraldseth, O; Jynge, P; Kristoffersen, A; Larsson, HB; Skjold, A; Vangberg, TR, 2004
)
0.32
", <10 mmHg) despite a small dosage of HbV."( Oxygen release from low and normal P50 Hb vesicles in transiently occluded arterioles of the hamster window model.
Cabrales, P; Intaglietta, M; Sakai, H; Tsai, AG; Tsuchida, E, 2005
)
0.33
" AP(4)A dose-response curve was to the left of that of ATP, and maximum response was greater than that produced by ATP."( Contractile activity of ATP and diadenosine tetraphosphate on urinary bladder in the rat: role of A1- and P2X-purinoceptors and nitric oxide.
Al-Hrasen, MN; El-Hadiyah, TM; Khattab, MM, 2007
)
0.34
"In light-adapted rats, intraretinal enhancements responded in a dose-response manner."( Toward clinical application of manganese-enhanced MRI of retinal function.
Berkowitz, BA; Jin, Y; Porchia, A; Roberts, R; Tofts, PS, 2010
)
0.36
" Hypo-osmolarity induced a dose-response (285-80 mOsm) increase of EnS-GLU which was detected after small osmolarity modifications (15 mOsm) and which was very marked (>1000%) after more intense osmolarity changes."( Osmosensitive response of glutamate in the substantia nigra.
Fuentes, A; Gonzalez-Hernandez, T; Moráles, I; Rodríguez, M, 2009
)
0.35
"There was a strong dose-response relation of plasma PLP concentration with plasma CRP."( Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study.
Lai, CQ; Mattei, J; Ordovas, JM; Shen, J; Tucker, KL, 2010
)
0.36
"A 19 wk, randomized crossover trial was conducted in 21 generally healthy men and postmenopausal women > or = 50 y to study the dose-response effects of walnut intake on biomarkers of antioxidant activity, oxidative stress, and nutrient status."( Chronic and acute effects of walnuts on antioxidant capacity and nutritional status in humans: a randomized, cross-over pilot study.
Blumberg, JB; Chen, CY; Lichtenstein, AH; Matthan, NR; McKay, DL; Yeum, KJ, 2010
)
0.36
" The proportional changes in MDA and Oxygen Radical Absorbance Capacity (ORAC) were consistent with a dose-response effect, although no significant within- or between-group differences were observed for these measures."( Chronic and acute effects of walnuts on antioxidant capacity and nutritional status in humans: a randomized, cross-over pilot study.
Blumberg, JB; Chen, CY; Lichtenstein, AH; Matthan, NR; McKay, DL; Yeum, KJ, 2010
)
0.36
" Therefore, interindividual differences in metabolism, and not in bioavailability, may be important sources of variability that need to be addressed in dosing guidelines."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.37
" Dose-response relationship was assessed by restricted cubic spline."( Association of vitamin B6, vitamin B12 and methionine with risk of breast cancer: a dose-response meta-analysis.
Kang, S; Wu, W; Zhang, D, 2013
)
0.39
" Linear dose-response relationship was found, and the risk of breast cancer decreased by 23% (P<0."( Association of vitamin B6, vitamin B12 and methionine with risk of breast cancer: a dose-response meta-analysis.
Kang, S; Wu, W; Zhang, D, 2013
)
0.39
" We also performed a random-effects dose-response meta-analysis."( Vitamin B6 and Cancer Risk: A Field Synopsis and Meta-Analysis.
Briarava, M; Mocellin, S; Pilati, P, 2017
)
0.46
" Study participants with elevated PAr experienced a higher risk of incident stroke in an essentially linear dose-response fashion."( The PAr index, an indicator reflecting altered vitamin B-6 homeostasis, is associated with long-term risk of stroke in the general population: the Hordaland Health Study (HUSK).
Meyer, K; Midttun, Ø; Nygård, O; Tell, GS; Ueland, PM; Ulvik, A; Vollset, SE; Zuo, H, 2018
)
0.48
" A total of 24 patients will be assigned into one of three dosing cohorts of eight patients (n = 6 for PP100-01 and NAC; n = 2 for NAC alone)."( Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomi
Dear, J, 2019
)
0.51
" In order to prevent immunological reactions which might be produced by multiple dosing of rMETase and to prolong the serum half-life of rMETase, the N-hydroxysuccinimidyl ester of methoxypolyethylene glycol propionic acid (M-SPA-PEG 5000) has been coupled to rMETase."( Development of Recombinant Methioninase for Cancer Treatment.
Han, Q; Hoffman, RM; Inagaki, K; Kudou, D; Li, S; Takakura, T; Takimoto, A; Tan, Y; Yagi, S, 2019
)
0.51
" Therefore, the present study aimed to trial a modified injection regime using more frequent dosing of BBG to improve outcomes in this model of GVHD."( P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
Adhikary, SR; Casolin, S; Cuthbertson, P; Geraghty, NJ; Sluyter, R; Watson, D, 2021
)
0.62
" The EEG was repeated after reaching maximum dosage of pyridoxine."( Pyridoxine or pyridoxal-5-phosphate treatment for seizures in glycosylphosphatidylinositol deficiency: A cohort study.
Aledo-Serrano, A; Bayat, A; Boßelmann, C; de Sain-van der Velden, MGM; Gardella, E; Gil-Nagel, A; Korff, CM; Lund, AM; Møller, RS; Thomas, A; Weber, Y, 2022
)
0.72
" Notably, there is a lack of studies on the general population and studies of the dose-response relationship."( Association of Pyridoxal 5'-Phosphate with Sleep-Related Problems in a General Population.
Ge, L; Kang, X; Luo, J; Zhang, D; Zhang, L, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
coenzymeA low-molecular-weight, non-protein organic compound participating in enzymatic reactions as dissociable acceptor or donor of chemical groups or electrons.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitorA DNA polymerase inhibitor that interferes with the action of a DNA-directed DNA polymerase (EC 2.7.7.7).
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
vitamin B6 phosphate
methylpyridinesAny member of the class of pyridines that carries at least one methyl substituent.
monohydroxypyridineA hydroxypyridine carrying a single hydroxy substituent.
pyridinecarbaldehyde
pyridinecarbaldehyde
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (24)

PathwayProteinsCompounds
Amino acid synthesis and interconversion (transamination)2343
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Vitamin B6 Metabolism515
Hypophosphatasia515
Vitamin B6228
Vitamin B6 metabolism ( Vitamin B6 metabolism )417
Nsp9 interactions (COVID-19 Disease Map)8330
Serine metabolism822
Metabolic Epileptic Disorders2589
Mycobacterium tuberculosis biological processes3962
Sulfur compound metabolism1929
Cysteine synthesis from O-acetylserine715
Cysteine synthesis from O-phosphoserine47
pyridoxamine anabolism08
Folic acid network070
Superpathway of pyridoxal 5'-phosphate biosynthesis and salvage014
Selenium micronutrient network095
Vitamin B12 metabolism050
Folate metabolism156
One-carbon metabolism013
Methionine de novo and salvage pathway148
GABA metabolism (aka GHB)1128
Neurotransmitter disorders819
Vitamin B6-dependent and responsive disorders219

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency9.07430.005612.367736.1254AID624032
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency33.49150.000657.913322,387.1992AID1259377
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency13.33220.000627.21521,122.0200AID743202
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency17.78280.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2X purinoceptor 1Homo sapiens (human)IC50 (µMol)10.00000.01922.346410.0000AID744382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2X purinoceptor 1Rattus norvegicus (Norway rat)EC50 (µMol)3.00000.05402.761310.0000AID152480
P2X purinoceptor 4Rattus norvegicus (Norway rat)EC50 (µMol)219.00002.30006.566710.0000AID150164
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Receptor-type tyrosine-protein phosphatase betaHomo sapiens (human)Kis5.66503.73005.66507.6000AID775020; AID775023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
protein dephosphorylationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
phosphate-containing compound metabolic processReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
glial cell migrationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
dephosphorylationReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
angiogenesisReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
monoatomic ion transportP2X purinoceptor 1Homo sapiens (human)
serotonin secretion by plateletP2X purinoceptor 1Homo sapiens (human)
regulation of vascular associated smooth muscle contractionP2X purinoceptor 1Homo sapiens (human)
apoptotic processP2X purinoceptor 1Homo sapiens (human)
signal transductionP2X purinoceptor 1Homo sapiens (human)
inseminationP2X purinoceptor 1Homo sapiens (human)
regulation of blood pressureP2X purinoceptor 1Homo sapiens (human)
neuronal action potentialP2X purinoceptor 1Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 1Homo sapiens (human)
platelet activationP2X purinoceptor 1Homo sapiens (human)
response to ATPP2X purinoceptor 1Homo sapiens (human)
synaptic transmission, glutamatergicP2X purinoceptor 1Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 1Homo sapiens (human)
ceramide biosynthetic processP2X purinoceptor 1Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2X purinoceptor 1Homo sapiens (human)
positive regulation of calcium ion import across plasma membraneP2X purinoceptor 1Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2X purinoceptor 1Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 1Homo sapiens (human)
response to hypoxiaP2X purinoceptor 2Homo sapiens (human)
response to ischemiaP2X purinoceptor 2Homo sapiens (human)
detection of hypoxic conditions in blood by carotid body chemoreceptor signalingP2X purinoceptor 2Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 2Homo sapiens (human)
neuromuscular junction developmentP2X purinoceptor 2Homo sapiens (human)
sensory perception of soundP2X purinoceptor 2Homo sapiens (human)
response to carbohydrateP2X purinoceptor 2Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 2Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 2Homo sapiens (human)
peristalsisP2X purinoceptor 2Homo sapiens (human)
response to ATPP2X purinoceptor 2Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 2Homo sapiens (human)
behavioral response to painP2X purinoceptor 2Homo sapiens (human)
skeletal muscle fiber developmentP2X purinoceptor 2Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 2Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 2Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 2Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
cadherin bindingReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
acid phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein bindingLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 1Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
protein bindingP2X purinoceptor 1Homo sapiens (human)
ATP bindingP2X purinoceptor 1Homo sapiens (human)
identical protein bindingP2X purinoceptor 1Homo sapiens (human)
suramin bindingP2X purinoceptor 1Homo sapiens (human)
protein-containing complex bindingP2X purinoceptor 1Homo sapiens (human)
ligand-gated calcium channel activityP2X purinoceptor 1Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 2Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 2Homo sapiens (human)
ATP bindingP2X purinoceptor 2Homo sapiens (human)
ligand-gated monoatomic ion channel activityP2X purinoceptor 2Homo sapiens (human)
identical protein bindingP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
plasma membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
specific granule membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
tertiary granule membraneReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
receptor complexReceptor-type tyrosine-protein phosphatase betaHomo sapiens (human)
cytoplasmLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytosolLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytoplasmic side of plasma membraneLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
sarcolemmaLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
extracellular exosomeLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
plasma membraneP2X purinoceptor 1Homo sapiens (human)
external side of plasma membraneP2X purinoceptor 1Homo sapiens (human)
secretory granule membraneP2X purinoceptor 1Homo sapiens (human)
specific granule membraneP2X purinoceptor 1Homo sapiens (human)
membrane raftP2X purinoceptor 1Homo sapiens (human)
postsynaptic membraneP2X purinoceptor 1Homo sapiens (human)
presynaptic active zone membraneP2X purinoceptor 1Homo sapiens (human)
glutamatergic synapseP2X purinoceptor 1Homo sapiens (human)
protein-containing complexP2X purinoceptor 1Homo sapiens (human)
plasma membraneP2X purinoceptor 1Homo sapiens (human)
plasma membraneP2X purinoceptor 2Homo sapiens (human)
apical plasma membraneP2X purinoceptor 2Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 2Homo sapiens (human)
postsynapseP2X purinoceptor 2Homo sapiens (human)
neuronal dense core vesicleP2X purinoceptor 2Homo sapiens (human)
receptor complexP2X purinoceptor 2Homo sapiens (human)
plasma membraneP2X purinoceptor 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (65)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID168664Fatty acid oxidation was measured using [3H]- palmitate in perfusing rat heart2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design and synthesis of novel pyridoxine 5'-phosphonates as potential antiischemic agents.
AID25046Apparent acid dissociation constant (pK) was determined1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Phosphonate analogues of pyridoxal phosphate with shortened side chains.
AID32373Inhibitory activity against ATP receptor in isolated perfused rat heart2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design and synthesis of novel pyridoxine 5'-phosphonates as potential antiischemic agents.
AID251394Percent reduction of collagen (5 ug/mL) induced platelet aggregation was determined at 0.5 mM concentration2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Pyridoxine as a template for the design of antiplatelet agents.
AID251367Percent reduction in infarct size after bolus injection at 0.1 mol/kg dose2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Pyridoxine as a template for the design of antiplatelet agents.
AID744382Antagonist activity at P2X1 receptor (unknown origin)2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.
AID775020Competitive inhibition of human GST-tagged LMW-PTP-B expressed in Escherichia coli JM 109 cells using p-nitrophenyl phosphate as substrate after 15 mins by microplate reader analysis2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B.
AID368571Inhibition of Trypanosoma cruzi trans-Sialidase2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening.
AID474369Inhibition of Trypanosoma cruzi recombinant trans-sialidase at 1 mM after 10 mins by MUNANA continuous fluorimetric assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
'Click chemistry' synthesis of a library of 1,2,3-triazole-substituted galactose derivatives and their evaluation against Trypanosoma cruzi and its cell surface trans-sialidase.
AID1664537Competitive inhibition of bovine LMW-PTP isoform B using para-Nitrophenyl phosphate as substrate at pH 5 by Lineweaver-Burk double reciprocal plot analysis2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
SAR of non-hydrolysable analogs of pyridoxal 5'-phosphate against low molecular weight protein tyrosine phosphatase isoforms.
AID251393Percent reduction of collagen (1 ug/mL) induced platelet aggregation was determined at 0.5 mM concentration2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Pyridoxine as a template for the design of antiplatelet agents.
AID626545Competitive inhibition of Cu2-amyloid beta (1 to 20) complex-induced DTBC oxidation by spectrophotometry2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Vitamin B6s inhibit oxidative stress caused by Alzheimer's disease-related Cu(II)-β-amyloid complexes-cooperative action of phospho-moiety.
AID744389Antagonist activity at human recombinant P2X3 receptor expressed in Xenopus oocytes assessed as inhibition of ATP-induced ion current at 10 uM incubated for 20 mins prior to ATP-induction by two-electrode voltage clamp assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID251419Percent reduction of thrombin receptor activating peptide (12 uM) induced platelet aggregation was determined at 0.5 mM concentration2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Pyridoxine as a template for the design of antiplatelet agents.
AID1160996Inhibition of recombinant Trypanosoma cruzi trans-sialidase catalytic N-terminal domain preincubated at 1 mM for 10 mins by continuous fluorimetric assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Design, synthesis and enzymatic evaluation of 3-O-substituted aryl β-D-galactopyranosides as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1664538Competitive inhibition of LMW-PTP isoform A (unknown origin)2020Bioorganic & medicinal chemistry letters, 08-15, Volume: 30, Issue:16
SAR of non-hydrolysable analogs of pyridoxal 5'-phosphate against low molecular weight protein tyrosine phosphatase isoforms.
AID775023Competitive inhibition of LMW-PTP-B (unknown origin)2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B.
AID150164The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 4 (P2X4) at 10 uM2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID187616Ability of compound to reduce the infarct size in rat administered via bolus at 0.02 mmol/kg2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design and synthesis of novel pyridoxine 5'-phosphonates as potential antiischemic agents.
AID251387Percent reduction of ADP (4 uM) induced platelet aggregation was determined at 0.5 mM concentration2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Pyridoxine as a template for the design of antiplatelet agents.
AID150148The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 2 (P2X2) at 30 uM2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID626547Competitive inhibition of Cu2-amyloid beta (1 to 16) complex-induced DTBC oxidation by spectrophotometry2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Vitamin B6s inhibit oxidative stress caused by Alzheimer's disease-related Cu(II)-β-amyloid complexes-cooperative action of phospho-moiety.
AID168862Glucose oxidation was measured using [C14] Glucose in perfusing rat heart2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design and synthesis of novel pyridoxine 5'-phosphonates as potential antiischemic agents.
AID1420837Inhibition of Trypanosoma cruzi trans-sialidase2018European journal of medicinal chemistry, Oct-05, Volume: 158The synthesis and kinetic evaluation of aryl α-aminophosphonates as novel inhibitors of T. cruzi trans-sialidase.
AID152480The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 1 (P2X1)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID744391Antagonist activity at mouse recombinant P2X1 receptor expressed in Xenopus oocytes assessed as inhibition of ATP-induced ion current at 10 uM incubated for 20 mins prior to ATP-induction by two-electrode voltage clamp assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,268)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903152 (50.29)18.7374
1990's1082 (17.26)18.2507
2000's1078 (17.20)29.6817
2010's718 (11.46)24.3611
2020's238 (3.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.46 (24.57)
Research Supply Index8.80 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index170.74 (26.88)
Search Engine Supply Index2.74 (0.95)

This Compound (68.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials140 (2.15%)5.53%
Trials0 (0.00%)5.53%
Reviews327 (5.02%)6.00%
Reviews0 (0.00%)6.00%
Case Studies95 (1.46%)4.05%
Case Studies0 (0.00%)4.05%
Observational6 (0.09%)0.25%
Observational0 (0.00%)0.25%
Other5,943 (91.28%)84.16%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC [NCT03654729]Phase 3291 participants (Actual)Interventional2018-11-07Terminated(stopped due to On 23 January 2020, the Sponsor announced that the United States (US) Food and Drug Administration (FDA) had issued a clinical hold in the US of the POLAR program.)
Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency [NCT04706013]Phase 315 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults [NCT03738943]Early Phase 19 participants (Actual)Interventional2019-02-07Completed
A Randomized, Double-Blind, Placebo-Controlled, Comparative Study to Evaluate the Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia in Patients With Schizophrenia and Schizoaffective Disorders [NCT00917293]Phase 253 participants (Actual)Interventional2009-05-31Terminated(stopped due to modified formulation under investigation)
Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Extracts of Plants Pregnenolone & Pyridoxal Phosphate for Treating Uterine Fibroids in Women of Reproductive Age and Women Pregnancy. [NCT04762316]66 participants (Actual)Interventional2019-01-01Completed
Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx® [NCT00933998]20 participants (Actual)Interventional2006-06-30Completed
MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery [NCT00402506]Phase 33,000 participants (Anticipated)Interventional2006-11-30Completed
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Cardiovascular and Cerebrovascular Effects of MC-1 in Patients Undergoing High-Risk Coronary Artery Bypass Graft (CABG) Surgery [NCT00157716]Phase 2900 participants Interventional2004-04-30Completed
Evaluation of the Effects of MC-1 Alone and in Combination With an ACE Inhibitor on Ambulatory Blood Pressure and Metabolic Function in Hypertensive Patients With Type 2 Diabetes Mellitus [NCT00157729]Phase 2160 participants Interventional2004-08-31Completed
A Double Blinded Randomised Three Armed Phase II Trial of PledOx in Two Different Doses in Combination With FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Advanced Metastatic Colorectal (Stage IV) Cancer [NCT01619423]Phase 1/Phase 2186 participants (Actual)Interventional2012-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01619423 (1) [back to overview]Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia)
NCT03654729 (10) [back to overview]Cumulative Dose of Oxaliplatin During Chemotherapy
NCT03654729 (10) [back to overview]Functional Impairment (in the Non-dominant Hand)
NCT03654729 (10) [back to overview]Mild, Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT03654729 (10) [back to overview]Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT03654729 (10) [back to overview]Overall Survival (OS)
NCT03654729 (10) [back to overview]Progression-free Survival (PFS)
NCT03654729 (10) [back to overview]Sensitivity to Touching Cold Items
NCT03654729 (10) [back to overview]Vibration Sensitivity on the Lateral Malleolus
NCT03654729 (10) [back to overview]Worst Pain in Hands or Feet
NCT03654729 (10) [back to overview]Overall Response Rate (ORR)
[back to top]

Cumulative Dose of Oxaliplatin During Chemotherapy

Mean cumulative dose of oxaliplatin administered per patient during mFOLFOX6 chemotherapy, 9 months after the first dose of IMP. (NCT03654729)
Timeframe: 9 months

Interventionmg/m^2 (Least Squares Mean)
PledOx (2 µmol/kg)780.69
PledOx (5 µmol/kg)803.54
Placebo764.52

[back to top]

Functional Impairment (in the Non-dominant Hand)

Mean change from baseline in the time to complete the grooved Pegboard with the non-dominant hand, at 9 months after the first dose of IMP. (NCT03654729)
Timeframe: Baseline and 9 months

Interventionseconds (Least Squares Mean)
PledOx (2 µmol/kg)9.68
PledOx (5 µmol/kg)14.24
Placebo12.01

[back to top]

Mild, Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)

"Percentage of patients (with mild, moderate or severe chronic CIPN) scoring 2, 3 or 4 in at least 1 of the first 4 items of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity-13-item subscale (FACT/GOG-NTX-13; i.e., FACT/GOG-NTX-4) 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy). The FACT/GOG-13 questionnaire includes 13 items that measure the severity and impact of symptoms of neurotoxicity over the past 7 days. Patients rate each item as 0 (not at all), 1 ( a little bit), 2 (somewhat), 3 (quite a bit) or 4 (very much). These 13 items are summed to create a total score, ranging from 0 to 52, with a higher score representing a worse outcome. The FACT/GOG-NTX-4 is a 4 item subscale targeting numbness, tingling or discomfort in hands and/or feet." (NCT03654729)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
PledOx (2 µmol/kg)43
PledOx (5 µmol/kg)40
Placebo42

[back to top]

Moderate or Severe Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN)

"Percentage of patients (with moderate or severe chronic CIPN) scoring 3 or 4 in at least 1 of the first 4 items of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity-13-item subscale (FACT/GOG-NTX-13; i.e., FACT/GOG-NTX-4) 9 months after the first dose of IMP (i.e. PledOx or placebo administered on Day 1, Cycle 1 of mFOLFOX6 chemotherapy). The FACT/GOG-13 questionnaire includes 13 items that measure the severity and impact of symptoms of neurotoxicity over the past 7 days. Patients rate each item as 0 (not at all), 1 ( a little bit), 2 (somewhat), 3 (quite a bit) or 4 (very much). These 13 items are summed to create a total score, ranging from 0 to 52, with a higher score representing a worse outcome. The FACT/GOG-NTX-4 is a 4 item subscale targeting numbness, tingling or discomfort in hands and/or feet." (NCT03654729)
Timeframe: 9 months

InterventionParticipants (Count of Participants)
PledOx (2 µmol/kg)31
PledOx (5 µmol/kg)27
Placebo25

[back to top]

Overall Survival (OS)

Patients with overall survival (NCT03654729)
Timeframe: An analysis at 36 months was planned. The analysis was performed based on available data at cut-off 31 August 2020 as the study was terminated early by the Sponsor

Interventionparticipants (Number)
PledOx (2 µmol/kg)9
PledOx (5 µmol/kg)9
Placebo16

[back to top]

Progression-free Survival (PFS)

Patients with progression-free survival (NCT03654729)
Timeframe: Analyses at 12 and 24 months were planned; the analysis was performed once based on available data at cut-off 31 August 2020 as the study was terminated early by the Sponsor

Interventionparticipants (Number)
PledOx (2 µmol/kg)40
PledOx (5 µmol/kg)36
Placebo36

[back to top]

Sensitivity to Touching Cold Items

Mean change from baseline in sensitivity to touching cold items on day 2, Cycle 4 of mFOLFOX6 chemotherapy, as assessed by the Cold Sensitivity Questionnaire (measuring sensitivity when touching or swallowing cold objects/fluid). 10 point scale from 0 meaning no sensitivity/discomfort at all to 10 meaning sensitivity/discomfort as bad as it can be. (NCT03654729)
Timeframe: Baseline and 8 weeks

InterventionScores on a scale (Least Squares Mean)
PledOx (2 µmol/kg)3.88
PledOx (5 µmol/kg)4.13
Placebo3.41

[back to top]

Vibration Sensitivity on the Lateral Malleolus

Mean change from baseline in vibration sense, on the lateral malleolus (left and right), using a graduated tuning fork, at 9 months after the first dose of IMP. When the tuning fork was struck against the ball of the thumb, the base of the tuning fork was placed over the appropriate bony surface (i.e., lateral malleolus left and right) and the patient was asked to indicate the moment when the vibration was no longer detected. The intensity at which the patient no longer detected the vibration is reported on a scale of 0 (minimum score, representing the maximum vibration amplitude) to 8 (maximum score, representing the minimum vibration amplitude) (NCT03654729)
Timeframe: Baseline and 9 months

InterventionScores on a scale (Mean)
PledOx (2 µmol/kg)-1.53
PledOx (5 µmol/kg)-1.61
Placebo-1.36

[back to top]

Worst Pain in Hands or Feet

Mean change from baseline in worst pain in hands or feet in the past week, using the Pain Assessment (Numerical Rating Scale (NRS)), at 9 months after the first dose of IMP. The NRS is a 10 point scale with 0 as no pain at all and 10 as pain as bad as you can imagine and evaluates the intensity of pain in hands and feet during the past week. A higher value means worse outcome. (NCT03654729)
Timeframe: Baseline and 9 months

InterventionScores on a scale (Least Squares Mean)
PledOx (2 µmol/kg)2.19
PledOx (5 µmol/kg)1.58
Placebo1.92

[back to top]

Overall Response Rate (ORR)

Percentage of patients with an overall response (complete response or partial response) according to RECIST v1.1 for target lesions and assessed by CT (preferred) or MRI. Complete response=disappearance of all target lesions; partial response >=30% decrease in the sum of the longest diameter of target lesions. (NCT03654729)
Timeframe: 12, 15 and 18 months

InterventionParticipants (Count of Participants)
Month 1272581391Month 1272581392Month 1272581390Month 1572581390Month 1572581391Month 1572581392Month 1872581390Month 1872581391Month 1872581392
MissingNoYes
PledOx (2 µmol/kg)22
PledOx (5 µmol/kg)19
Placebo19
PledOx (2 µmol/kg)6
PledOx (5 µmol/kg)13
Placebo12
PledOx (2 µmol/kg)13
PledOx (5 µmol/kg)12
Placebo8
PledOx (2 µmol/kg)9
PledOx (5 µmol/kg)14
Placebo7
PledOx (2 µmol/kg)7
PledOx (5 µmol/kg)7
Placebo3
PledOx (5 µmol/kg)2
Placebo2
PledOx (2 µmol/kg)2
PledOx (5 µmol/kg)3
Placebo0
PledOx (2 µmol/kg)1
PledOx (5 µmol/kg)0
Placebo1

[back to top]